Opposite Role of Kindlin-1 and Kindlin-2 in Lung Cancers

Jun Zhan1,2, Xiang Zhu1,3, Yongqing Guo5*, Yunling Wang1,4, Yuxiang Wang1,3, Guangliang Qiang5, Miaomiao Niu1,2, Jinxia Hu1,2, Juan Du1,2, Zhilun Li5, Jia Cui1,2, Bo Ma1,2, Weigang Fang1,3, Hongquan Zhang1,2*

1 Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education of Beijing, Beijing, People’s Republic of China, 2 Laboratory of Molecular Cell Biology and Tumor Biology, Department of Anatomy, Histology and Embryology, Peking University Health Science Center, Beijing, People’s Republic of China, 3 Department of Pathology, Peking University Health Science Center, Beijing, People’s Republic of China, 4 Institute of Cardiovascular Research, Peking University Health Science Center, Beijing, People’s Republic of China, 5 Department of Thoracic Surgery, Sino-Japan Friendship Hospital, Beijing, People’s Republic of China, 6 Unit for Clinical Molecular Biology, Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden

Abstract

Lung cancer is highly heterogenous and is composed of various subtypes that are in diverse differential stages. The newly identified integrin-interacting proteins Kindlin-1 and Kindlin-2 are the activators of transmembrane receptor integrins that play important roles in cancer progression. In this report we present the expression profiles of Kindlin-1 and Kindlin-2 in lung cancers using patient specimens and established their correlation with lung cancer progression. We found that Kindlin-1 was expressed in epithelia-derived non-small-cell lung cancer, especially in squamous cell lung cancer but expressed at low levels in poorly differentiated large cell lung cancer. However, Kindlin-2 was highly expressed in large cell lung cancer. Both Kindlin-1 and Kindlin-2 were found not expressed or expressed at very low levels in neuroendocrine-derived small cell lung cancer. Importantly, the Kindlin-1 expression level was positively correlated with the differentiation of squamous cell lung cancer. Surprisingly, we found that the very homologous Kindlin family proteins, Kindlin-1 and Kindlin-2, displayed counteracting functional roles in lung cancer cells. Ectopic expression of Kindlin-1 in non-small-cell lung cancer cells inhibited in vitro cell migration and in vivo tumor growth, while Kindlin-2 promoted these functions. Mechanistically, Kindlin-1 inhibited epithelial to mesenchymal transition in non-small-cell lung cancer cells, while Kindlin-2 enhanced epithelial mesenchymal transition in these cells. Taken together, we demonstrated that Kindlin-1 and Kindlin-2 differentially regulate lung cancer cell progression. Further, the expression levels of Kindlin-1 might be potentially used as a marker for lung cancer differentiation and targeting Kindlin-2 might block the invasive growth of large cell lung cancer.

Introduction

Lung cancer is a complicated disease that can be histologically classified into small cell lung carcinoma (SCLC) which represents nearly 20% of lung cancer, and the major part is non-small-cell lung cancer (NSCLC) which represents more than 80% of lung cancer [1]. NSCLC encompass squamous cell carcinoma (SCC), adenocarcinoma (AC), and large cell carcinoma (LC) [2]. Highly differentiated, moderate differentiated and poorly differentiated carcinomas can be seen in SCC and AC. Lung cancer is quite heterogeneous in tumor growth, invasion and metastasis as well as in the outcomes after treatment. Lung cancer in different differentiation status displayed discrepancy in malignancy, e.g., low-differentiated lung carcinomas are more malignant than high-differentiated cancers, which is fast growing and highly metastatic.

Fermitin family member 1 (FERMT1) encoding Kindlin-1 is a FERM (4.1-Ezrin-Radixin-Moesin)-containing protein that belongs to Kindlin family. Kindlins are integrin-interacting proteins that regulate integrin activation via interaction with the integrin β subunit cytoplasmic domain [3,4]. Kindlin-2 encoded by FERMT2 was found to control a bidirectional signaling via integrin [5]. Kindlin was designated from Kindler Syndrome that was coined in 1954 featured by a combination of epidermal atrophy, widened capillaries and mottled cutaneous pigmentation [6]. Mutations of Kindlin-1 had been identified as the cause of Kindler Syndrome [7,8]. Until recently Kindlin family member have been connected to the progression of tumors [9]. Kindlin-2 has been shown to be expressed in malignant mesothelioma and regulates adhesion and migration [10], and the expression level of Kindlin-2 is related to the sensitivity of prostate cancer cells to cisplatin-induced cell death [11]. Kindlin-2 expression was found correlated with tumor invasion, lymph node metastasis, and patient outcome in gastric cancer [12]. Kindlin-1 has been found overexpressed in 60% of lung cancer and 70% of colon cancer as examined by RNA expression levels out of ten patients [9]. Very recently, Sin et al demonstrated that Kindlin-1 plays a role in breast cancer growth and lung metastasis [13]. Besides expression in tumor cells, Kindlin-2 was also found to be highly expressed in the tumor stroma in bladder cancers [14]. However, while Kindlin-1 and Kindlin-2 are related to cancer progression,
Kindlin-3 is contributory in the hematopoietic disorders [15–19]. Kindlin-2 expressed broadly in endothelial and vesicular smooth muscle [3,20], and is an essential component of intercalated discs that is required for vertebrate cardiac structure and function [21]. However, so far little is known about the roles of Kindlin-1 and Kindlin-2 in lung cancer progression.

In this study we aim to answer firstly that if Kindlin-1 and Kindlin-2 play a role in lung cancer progression. Due to the high heterogeneity of lung cancer we also want to answer that if Kindlin-1 and Kindlin-2 differentially expressed in various types of lung cancer and functions distinctly in lung cancer cells. To this end, we have investigated the expression of Kindlin-1 and Kindlin-2 in a panel of lung cancer tissue samples and paid attention to compare the relative expression levels of Kindlin-1 and Kindlin-2 in the same patient. Intriguingly, we identified a reciprocal role of Kindlin-1 and Kindlin-2 in the regulation of tumor progression in both cells and animals. Taken together, our findings provide a new understanding of Kindlin-1 and Kindlin-2 in lung cancer cell progression and may help for future drug design towards lung cancer therapeutics.

Materials and Methods

Ethics

The Ethics Committee of Peking University Health Science Center has approved the current study for mouse experiments (Permit Number: LA2011-73). The Ethics Committee of Sino-Japan Friendship Hospital has approved the current study using lung cancer patient tumors for research purposes (Permit Number: ZRLW-5). The procedures for handling mice and human materials were in accordance with the ethical standard of the Helsinki Declaration of 1975, and the revised in 1983.

Expression vectors, cell culture and stable transfection cell lines

Kindlin-1 full-length cDNA was cloned from a human placenta cDNA library using primers: CAGAAATCCATCTGCTGATC-CAATGACCTTTAC (forward primer) and GATCTAGAT-CAATGCTGACCGCCGGTCAA (reverse primer). PCR product was cloned into PCRII vector, and then further cloned into pCMV10-3 xFlag vector (Sigma) using HindIII-EcoRI sites. U1752, H1299, A549 and U1810 cell lines were purchased from ATCC in the USA or Cell Collection Center of Peking Union Medical School in China and were cultured in RPMI1640 medium (Invitrogen) with 10% FBS and 50 μg/ml gentamycin. Cells were grown in 75 cm² culture flasks or 60-mm dishes at 37 °C in humidified atmosphere with 5% (v/v) CO₂. Media were changed every two days. SCLC were seeded on the upper surface of the Transwell. After 6 h incubation in migration buffer (RPMI1640, 2 mM CaCl₂, 1 mM MgCl₂, 0.2 mM MnCl₂, and 0.5% BSA) at 37 °C, we performed the cell migration assay. First, Collagen type I were used as a substrate on the Transwell chambers (Costar) with 8 μm pore size. 80% of cell lysates was added to 20% of 5x SDS loading buffer, then resolved by 10% SDS-PAGE gel and blotted onto PVDF membranes (pore size 0.45 μm). The primary antibodies anti-Kindlin-1 mouse monoclonal antibody (1:500 dilution; Clone 4A5.14, Milipore; USA), anti-Kindlin-2 mouse monoclonal antibody (1:1000 dilution; Clone 3A3, Milipore, USA), anti-Vimentin rabbit monoclonal antibody (1: 2000 dilution; Epitomics, USA), anti-E-cadherin rabbit monoclonal antibody (1:3000 dilution; Epitomics, USA), anti-N-cadherin rabbit monoclonal antibody (1:10000 dilution; Epitomics, USA), anti-Flag-monoclonal antibody (1:10000 dilution; Clone M2, Sigma, USA) and anti-β-actin mouse monoclonal antibody (1:10000 dilution; Clone C4, Santa Cruz, USA) were incubated with the membranes separately under rotation. After thorough washing, membranes were further incubated with corresponding secondary antibodies recognizing either rabbit or mouse IgG (Jackson Laboratories, USA). Finally, the bands were visualized by the enhanced chemiluminescence (ECL).

Quantitative PCR

Quantitative PCR (qPCR) assays were performed to detect the expression of Kindlin-1 mRNA in lung tumor tissues. In brief, the normal tissue and lung tumor total mRNAs were isolated by Trizol (Invitrogen, Carlsbad, CA, USA), and 2 μg of total RNA was reverse transcribed using M-MLV reverse transcriptase (Promega, CA, USA). Then PCR was performed using Taq PCR MasterMix (Tiangen, China) with the settings as: 94 °C 2 min; 94 °C 30 sec, 60 °C 30 sec, 72 °C 30 sec, for 30 cycles; 72 °C 5 min. The primer sequences were as follows: for human Kindlin-1, forward: TCTGTGTGGAGGAGTGATGC, reverse: AAGCCAG-CAATGCTTCTGTT; for actin, forward: CTTGACGTTGCT- TACTCCCTTC, reverse: GCCATCTGTGTTCTCGGAAGTC. PCR products were analyzed by 2.5% agarose gel electrophoresis in the presence of ethidium bromide for visualization. Quantitative PCR was also used to identify the changes of MMPs mRNA level induced by Kindlin-1 and Kindlin-2 in H1299 cell line. MMP-2 forward: AGCTCCCGGAAAAGATTGTG, reverse: GGTG-CTGGCTGAGTAG-ATCC; MMP-7 forward: GTCTCGGAG-GAGATGCTCAC, reverse: TACCCAAA-GAATGGCCAAGT; MMP-9 forward: TCTTCCCTGGAGACCTGAGA, reverse: ATTTCCGACCTCTCACGATC. Relative fold changes in qPCR were determined by the ΔΔCt method.

Cell motility assays

Transwell chambers (Costar) with 8 μm pore size were used to perform the cell migration assay. First, Collagen type I were used to coat the lower surface of Transwell membranes for 1 h at room temperature. Then, H1299 cells stable transfected with Flag-BAP (bacterial alkaline phosphatase), Flag-Kindlin-1 and Flag-Kindlin-2 were seeded on the upper surface of the Transwell. After 6 h incubation in migration buffer (RPMI1640, 2 mM CaCl₂, 1 mM MgCl₂, 0.2 mM MnCl₂, and 0.5% BSA) at 37 °C in humidified atmosphere with 5% CO₂, the Transwell membranes were fixed with 4% formaldehyde for 15 min and stained by crystal violet for 10 min. At last, 6 microscopic fields were randomly chosen for counting the migrated cells.

Western blot analysis

PBS/Tris lysis buffer with the presence of protease cocktail inhibitors (Roche Diagnostics, GmbH) was used to extract total cell lysates. 80% of cell lysates was added to 20% of 5x SDS loading buffer, then resolved by 10% SDS-PAGE gel and blotted onto PVDF membranes (pore size 0.45 µm). The primary antibodies anti-Kindlin-1 mouse monoclonal antibody (1:500 dilution; Clone 4A5.14, Milipore; USA), anti-Kindlin-2 mouse monoclonal antibody (1:1000 dilution; Clone 3A3, Milipore, USA), anti-Vimentin rabbit monoclonal antibody (1: 2000 dilution; Epitomics, USA), anti-E-cadherin rabbit monoclonal antibody (1:3000 dilution; Epitomics, USA), anti-N-cadherin rabbit monoclonal antibody (1:10000 dilution; Epitomics, USA), anti-Flag-monoclonal antibody (1:10000 dilution; Clone M2, Sigma, USA) and anti-β-actin mouse monoclonal antibody (1:10000 dilution; Clone C4, Santa Cruz, USA) were incubated with the membranes separately under rotation. After thorough washing, membranes were further incubated with corresponding secondary antibodies recognizing either rabbit or mouse IgG (Jackson Laboratories, USA). Finally, the bands were visualized by the enhanced chemiluminescence (ECL).
For cell wound healing experiment, 48 h after transfection monolayer cells were scratched using a standard 100 µl pipette tip. The wounded monolayers were washed twice to remove non-adherent cells with 0.1 M PBS (pH7.2). Twelve h later the wound was observed with a 20×objective (Nikon, Japan) and measured for the width of the cell wounds. Six microscopic fields for each dish were observed and photographed.

Immunohistochemistry (IHC)

Lung tumor slides obtained from Sino-Japan Friendship Hospital were all formalin-fixed and paraffin-embedded. Deparaffinization and hydration were performed and followed by abolishing endogenous peroxidase activity using 0.3% hydrogen peroxide for 30 min and microwave for antigen retrieval in 10 mM sodium citrate buffer (pH6.0) for 20 min. We used affinity-purified polyclonal anti-Kindlin-1 (PKU Animal Facility) antibody at 2 µg/ml and monoclonal anti-Kindlin-2 (Milipore, USA) at 2 µg/ml to perform these experiments. The primary antibody was used at 4°C overnight. Then PV9000 2-step plus Poly-HPHR Anti-mouse/rabbit IgG Detection System (Zhong Shan Jin Qiao) was applied. The streptavidin-biotin-peroxidase method was used for detection and diaminobenzidine was applied for substrate (ChemMate Detection Kit, DAKO). Hematoxylin was used for counterstain. Negative controls were performed by omitting the use of primary antibody.

Evaluation of immunohistochemistry

Two independent pathologists evaluated all immunostainings and a consensus justification based on discussion was recorded. The assessment was classified into 4 grades: no reactivity marked as 0, faint reactivity as 1+, moderate reactivity as 2+, and strong reactivity as 3+.

Table 1. Clinical-pathological data of lung cancer patients.

| Feature                      | No. of Patients |
|------------------------------|-----------------|
| Sex:                         | n=140           |
| Male                         | 104             |
| Female                       | 36              |
| Age:                         |                 |
| 30–39                        | 1               |
| 40–49                        | 10              |
| 50–59                        | 33              |
| 60–69                        | 58              |
| 70–79                        | 35              |
| 80–                          | 3               |
| Pathological diagnosis:      |                 |
| Non- small cell lung carcinoma | Well differentiated | 4 |
| Squamous cell lung carcinoma  | Moderate differentiated | 50 |
| Well differentiated          | 4               |
| Moderate differentiated      | 50              |
| Poorly differentiated        | 11              |
| Adenocarcinoma               |                 |
| Well differentiated          | 7               |
| Moderate differentiated      | 28              |
| Poorly differentiated        | 8               |
| Large cell carcinoma         | 12              |
| Small cell lung carcinoma    | 20              |

doi:10.1371/journal.pone.0050313.t001

For cell wound healing experiment, 48 h after transfection monolayer cells were scratched using a standard 100 µl pipette tip. The wounded monolayers were washed twice to remove non-adherent cells with 0.1 M PBS (pH7.2). Twelve h later the wound was observed with a 20×objective (Nikon, Japan) and measured for the width of the cell wounds. Six microscopic fields for each dish were observed and photographed.

In vivo xenograft tumor growth experiment

Balb/c nude mice were implanted subcutaneously into the flank with 1×10⁶ cells which are stably overexpressing Kindlin-1, Kindlin-2 and the control vector separately. Tumors were measured for their sizes in eighteen days and continue to record for the indicated time. Mice were sacrificed using euthanasia when tumor growth at 1 cm in diameter. Tumors were taken out and weighted.

Statistical analysis

Statistical analyses for patient materials were performed with Kruskal-Wallis test and Statistical analyses for paired samples employed Student’s t test. All statistical analyses were using SPSS version14.0. Results were considered statistically significant at the level of P<0.05.

Results

Kindlin-1 is expressed in normal lung tissue and different subtypes of lung cancer

Kindlin-1 expression in lung cancer has been preliminarily suggested. However, nothing is known in detail for Kindlin-1 expression in various subtypes of lung cancer patients. To understand the possible involvement of Kindlin-1 and Kindlin-2 in lung cancer progression, we first examined the expression of Kindlin-1 in lung cancer patient tissues using immunohistochemistry (IHC) with an affinity-purified polyclonal Kindlin-1 antibody, with normal lung tissues as control. We found that Kindlin-1 was not detectable in normal pulmonary alveoli and weak signal in normal lung blood vessels was seen (Fig. 1a-A). Interestingly, Kindlin-1 was found highly expressed in the cytoplasm and nuclei of cone-shaped cells and spindle cells distributed in columnar epithelia (Fig. 1a-B). However, Kindlin-1 was found weakly expressed in the columnar cells, goblet cells and not expressed in the basement membrane. In lung tumor tissues, Kindlin-1 was not detectable.
found highly expressed in the cytoplasm as well as membrane of SCC (Fig. 1a-C). Furthermore, Kindlin-1 was found moderately expressed in the cytoplasm of tumorous glandular epithelia in AC (Fig. 1a-D) and weakly expressed in LCC (Fig. 1a-E). Surprisingly, no expression of Kindlin-1 at all in SCLC was observed (Fig. 1a-F) (Table 2).

Furthermore, we examined the Kindlin-1 mRNA expression even freshly prepared tumor tissues from SCC, AC and SCLC of lung cancer patients. We found that SCC showed higher levels of Kindlin-1 expression than AC, and SCLC displayed the lowest expression of Kindlin-1 among various types of lung cancer patients examined (Fig. 1b).

Encouragingly, the above Kindlin-1 expression profile as determined either by immunohistochemistry or qPCR was further supported by re-analizing Kindlin-1 mRNA expression profile in patient’s datasets from Oncomine Database (www.oncomine.com).

**Table 2.** Kindlin-1 and Kindlin-2 expressions during lung cancer progression.

| Features                          | N = 140 KINDLIN-1 expression | p value | KINDLIN-2 expression | p value |
|-----------------------------------|------------------------------|---------|----------------------|---------|
|                                   | 0 | 1+ | 2+ | 3+ | 0 | 1+ | 2+ | 3+ |
| Tumor origin                      |                             |         |                      |         |
| Epithelial-derived: NSCLC         | 120(85.71%) 10(8.33%) 45(35.70%) 50(41.67%) 15(12.50%) | <0.0001 | 38(31.67%) 55(45.83%) 21(17.50%) 6(5.00%) | 0.0197 |
| Neuroendocrine-derived: SCLC      | 20(14.29%) 13(65.00%) 6(30.00%) 1(5.00%) | 0.00%   | 11(55.00%) 8(40.00%) 1(5.00%) | 0.00%   |
| Tumor tissue sub types            |                             |         |                      |         |
| Squamous cell carcinoma           | 65(46.42%) 1(1.54%) 14(21.54%) 37(56.92%) 13(20.00%) | <0.0001 | 26(40.00%) 31(47.69%) 8(12.31%) | 0.00% 0.0003 0.0001 |
| Adenocarcinoma                    | 43(30.71%) 6(13.95%) 23(53.49%) 12(27.91%) 2(4.65%) | 0.00%   | 10(23.26%) 23(53.49%) 18(8.60%) 2(4.65%) |
| Large cell undifferentiated cancer | 12(8.57%) 3(25.00%) 8(66.67%) 1(8.33%) | 0.00%   | 2(16.67%) 1(8.33%) 5(41.67%) 4(33.33%) |
| Small cell lung carcinoma         | 20(14.29%) 13(65.00%) 6(30.00%) 1(5.00%) | 0.00%   | 11(55.00%) 8(40.00%) 1(5.00%) | 0.00%   |
| Tumor differentiation             |                             |         |                      |         |
| Differentiated carcinoma          | 108(90%) 7(6.48%) 37(34.26%) 49(45.37%) 15(13.89%) | <0.0001 | 36(33.33%) 54(50.00%) 16(14.81%) 2(1.85%) | <0.0001 |
| Large cell undifferentiated cancer | 12(10%) 3(25.00%) 8(66.67%) 1(8.33%) | 0.00%   | 2(16.67%) 1(8.33%) 5(41.67%) 4(33.33%) |
| Well differentiated squamous cell carcinoma | 4(2.86%) | 0.00% | 0.00% | 3(75.00%) 1(25.00%) | 0.0024 | 1(25.00%) 2(50.00%) 1(25.00%) | 0.00% 0.2852 |
| Moderate differentiated squamous cell carcinoma | 50(35.71%) | 0.00% | 7(14.00%) 32(64.00%) 11(22.00%) | 0.00% | 20(40.00%) 23(46.00%) 7(14.00%) | 0.00% |
| Poorly differentiated squamous cell carcinoma | 11(7.86%) 1(9.09%) 7(63.64%) 2(18.18%) 1(9.09%) | 0.00% 0.00% | 5(45.45%) 6(54.55%) | 0.00% | 0.00% |
| Well differentiated adenocarcinoma | 7(5%) 3(42.86%) 1(14.29%) 1(14.29%) 2(28.57%) | 0.8532 | 2(28.57%) 2(28.57%) 2(28.57%) 1(14.29%) 0.1759 |
| Moderate differentiated adenocarcinoma | 28(20%) | 2(7.14%) 16(57.14%) 10(35.71%) | 0.00% | 7(25.00%) 18(64.29%) 2(7.14%) 1(3.57%) |
| Poorly differentiated adenocarcinoma | 8(5.72%) 1(12.50%) 6(75.00%) 1(12.50%) | 0.00% | 1(12.50%) 3(37.50%) 4(50.00%) | 0.00% |

**Kruskal-Wallis test (two sided)** Both of Kindlin-1 and Kindlin-2 expression are higher in NSCLC than in SCLC (p < 0.0001). Among NSCLC, Kindlin-1 expression is low in LCC, higher in AC, and the highest is seen in SCC (p < 0.0001). But Kindlin-2 has reverse expression trend: the level of Kindlin-2 is low in SCC, higher in AC and the highest in LCC (p < 0.0001). The level of Kindlin-1 expression is also correlated with the level of lung cancer differentiation: differentiated SCC and AC have higher Kindlin-1 expression than undifferentiated SCC and AC. The high level of Kindlin-1 expression and poorly differentiated SCC has low level of Kindlin-1 (p = 0.0024). This phenomenon is not obvious in AC (p = 0.8523). Kindlin-2 expression has no obvious relationship with the differentiation of lung cancers (p = 0.1759).

doi:10.1371/journal.pone.0050313.t002
After analyzing the Hou and Garber lung cancer patient’s Affymetrix datasets, we found that Kindlin-1 expression in different types of NSCLC at mRNA level was significantly increased (Fig. 1c), which is in agreement with the above IHC results. These data suggest that Kindlin-1 is indeed highly expressed in SCC by examination of different patient co-horts.

Kindlin-1 expression is correlated with cell differentiation in SCC but not in AC

Aforementioned findings indicated that even within SCC, Kindlin-1 expression is heterogeneous. This suggests that Kindlin-1 expression may vary with the change of cell differentiation in lung cancer. To this end, we analyzed the Kindlin-1 expression in SCC with different stages of cell differentiation. Interestingly, we found that Kindlin-1 is highly expressed in the well differentiated SCC than the moderate differentiated SCC (Fig. 2-A and -B); and the moderate differentiated SCC expressed higher Kindlin-1 than the poorly differentiated SCC (Fig. 2-B and -C). However, this tendency of Kindlin-1 expression found in SCC was not applicable to AC (data not shown). Taken together, these data indicate that the higher differentiation stage responds to the higher expression of Kindlin-1 in SCC (Table 2).

Kindlin-1 and Kindlin-2 are differentially expressed in different subtypes of lung cancer

Until now there is no report on Kindlin-2 expression in lung cancer cell lines as well as in lung cancer patients. It is of interest to know if both Kindlin-1 and Kindlin-2 are expressed in lung cancer patients. To this end, we examined the Kindlin-2 expression in the same panel of patient specimens aforementioned. While Kindlin-2 was found expressed in the blood vessels of the normal lung tissues (Fig. 3a-A), Kindlin-2 was found highly expressed in the cytoplasm and nuclei of cone-shaped cells (Fig. 3a-B) similar to the Kindlin-1 staining as shown in Fig. 1a-B. This indicates that both Kindlin-1 and Kindlin-2 are expressed in the normal bronchia epithilium. Interestingly, Kindlin-2 expression pattern is quite different from that of Kindlin-1 in SCC. Instead of expressed in SCC and AC, Kindlin-2 was found highly expressed in the tumor stroma (Fig. 3a-C and -D), which contrast sharply to the expression pattern of Kindlin-1 in these types of lung cancer. Furthermore, Kindlin-2 was found highly expressed in LCC at the cell membrane and the surrounding tumor stroma compared to the weak expression of Kindlin-1 in LCC (Fig. 3a-E). In addition, low or no positive staining of Kindlin-2 was observed in SCLC (Fig. 3a-F), which is similar to the Kindlin-1 staining in the same cell type (Fig. 1a-F). These IHC results were further strengthened by the re-analyses of Kindlin-2 mRNA expression on Oncomine databases Hou lung and Garber lung (Fig. 3b). In the series of SCC patient’s tissue sections, Kindlin-1 was strongly expressed in the tumor cells, while Kindlin-2 was found expressed mainly in the tumor stroma (Fig. 3c-A, -B). These observations indicate that Kindlin-1 and Kindlin-2 are differentially expressed in lung cancer cells.

Table 2 summarized the expression of Kindlin-1 and Kindlin-2 in the tumors of various lung cancer patients. Kindlin-1 expression was positive in 84% of lung cancer patients. For the various tumor subtypes, both Kindlin-1 and Kindlin-2 showed high positive rate in NSCLC than in SCLC ($p<0.0001$). Interestingly, within NSCLC Kindlin-1 expressed at low levels in LCC, moderate in AC, and the highest expression of Kindlin-1 was found in SCC ($p<0.0001$). However, Kindlin-2 has a reciprocal expression profile: the expression level of Kindlin-2 is low in SCC, moderate in AC and the highest expression of Kindlin-2 was observed in LCC ($p<0.0001$). Intriguingly, the Kindlin-1 expression was found correlated with the differentiation of tumors. SCC, composed of squamous epithelia, and AC composed of glandular epithelia were exhibited higher Kindlin-1 expression than LCC that is classified as undifferentiated carcinoma ($p<0.0001$). Furthermore, well differentiated SCC has a higher Kindlin-1 expression than poorly differentiated SCC ($p=0.0024$). In comparison, no correlation was identified for Kindlin-1 expression with differentiation for AC ($p=0.8523$). Similarly, Kindlin-2 expression was not found to be correlated with the differentiation of different subtypes of lung cancer ($p=0.1759$).

Kindlin-1 and Kindlin-2 oppositely regulate lung cancer cell progression in vitro

Given that Kindlin-1 and Kindlin-2 are differentially expressed in lung cancer cells, it is tempting to understand whether Kindlin-1 and Kindlin-2 also function differentially to regulate lung cancer cell progression. We previously found that Kindlin-2 was highly expressed at tumor invasive front in malignant mesothelioma [10]. To this end, we examined the expression of Kindlin-1 and Kindlin-2 in the de novo SCC that are localized at the secondary sites from the intra-lung dissemination of a SCC patient. As shown in Fig. 4a-A, Kindlin-1 was strongly expressed at the tumor mass of de novo SCC but weakly expressed at the tumor invasive front. However, Kindlin-1 staining is concentrated in the nuclei of cells at tumor invasive front of the de novo SCC, suggesting a cytoplasm to nucleus transition may exist for Kindlin-1 (Fig. 4a-A.Arrowed). In contrast, Kindlin-2 was not found expressed in the similar type of structure from the same patient (Fig. 4a-B). Interestingly, a cytoplasm to nucleus transition of Kindlin-2 was also found at the
tumor invasive front (Fig. 4a-B.Arrowed). Collectively, these data suggest that Kindlin-1 but not Kindlin-2 is involved in the regulation of lung cancer cell colonization in SCC. Therefore, we continued to characterize the differential role of Kindlin-1 and Kindlin-2 in the regulation of lung cancer progression. We first detected the expressions of Kindlin-1 and Kindlin-2 as well as epithelial to mesenchymal transition (EMT) markers E-cadherin and Vimentin in lung cancer cell lines derived from SCC, AC and LCC and found that Kindlin-1 and Kindlin-2 were differentially expressed in lung cancer cell lines (Fig. 4b). We then established H1299 cells that stably overexpressed Kindlin-1. We found that EMT markers N-cadherin and Vimentin were downregulated in lung cancer H1299 cells stably overexpressing Kindlin-1 compared with the control cells expressing Flag-BAP (Fig. 4c), suggesting a role of Kindlin-1 in inhibition of EMT program in lung adenocarcinoma cells. Furthermore, to scrutinize the differential role of Kindlin-1 and Kindlin-2 in the regulation of lung cancer cell motility, we performed the hepatatotic migration assay on type I collagen that mediates β1 integrin-related cell migration. We found that Kindlin-1 inhibited while Kindlin-2 promoted H1299 cell migration in a Transwell assay (Fig. 4d). Meanwhile the distinct role of Kindlin-1 and Kindlin-2 in the regulation of lung cancer cell invasion was examined by determination of the expression of metalloproteinases including MMP7, MMP9 and MMP13. MMP7 and MMP9 were found to be downregulated with the ectopic expression of Kindlin-1, whereas MMP7 and MMP13 were upregulated with the ectopic expression of Kindlin-2 (Fig. 4e). In a transient transfection, overexpression of Kindlin-1 led to downregulation of N-cadherin (Fig. 4f left panel), suggesting an inhibitory role of Kindlin-1 on EMT occurrence. However, knockdown of endogenous Kindlin-2 decreased the level N-cadherin (Fig. 4f left panel), an effect that is equivalent to the overexpression of Kindlin-1. Furthermore, we examined the expression levels of Kindlin-2 in primary and secondary LCC and found that Kindlin-2 was strongly expressed in lymph nodes of metastasized LCC (Fig. 4g-B, arrowed) compared to the primary tumor from the same patient (Fig. 4g-A). This finding suggested that high level of Kindlin-2 expression may correspond to a high potential of LCC invasion. Taken together, these data indicated that the differential expressions of Kindlin-1 and Kindlin-2 in lung cancer patients correspond to an opposite regulation on cell migration as well as on the cell invasive capability.

Kindlin-1 and Kindlin-2 oppositely regulate lung cancer cell growth in an in vivo mouse xenograft model

Based on the above finding that Kindlin-1 and Kindlin-2 were differentially expressed in lung cancer patient specimens, and oppositely regulated lung cancer cell migration in vitro, we were eager to know whether Kindlin-1 and Kindlin-2 play a distinct role in the regulation of tumor growth in vivo. To this end, the mouse tumor xenografts with Kindlin-1 overexpression grew slower and the sizes of tumors were smaller than that of the control (Fig. 5a and b). However, tumors with Kindlin-2 overexpression grew much faster and the sizes of tumors were much larger than that of the control (Fig. 5a and b). Interestingly, tumor tissues recovered from the mouse xenografts also displayed increased N-cadherin and Vimentin expression in the Kindlin-2 overexpressing tumors, with no changes for N-cadherin and Vimentin in Kindlin-1 overexpressed or the control tumors (Fig. 5c). These data clearly demonstrated that Kindlin-1 and Kindlin-2 not only oppositely regulated tumor growth but also the tumor invasive potential in the in vivo mouse xenograft model.

Discussion

Kindlin-1 expression had been known to be related to lung cancer for many years [9]. However, until now there is no detailed study of Kindlin-1 expression in various types of lung cancer. In this report, we scrutinized the Kindlin-1 expression in NSCLC including SCC, AC and LCC as well as SCLC. Our findings have demonstrated that Kindlin-1 expression in lung cancer is correlated with the origin of the cells. For example, Kindlin-1 is higher expressed in epithelium-originated NSCLC but not expressed or lower expressed in neuroendocrine-originated SCLC, suggesting that Kindlin-1 is mainly expressed in epithelia originated SCC and AC. In comparison, LCC is non-squamous, non-adenomatous type of lung cancer that is undifferentiated and is usually highly malignant [22]. Interestingly, in this report Kindlin-1 expression was identified higher in SCC than that of AC and LCC. In agreement with this finding, data from Oncomine cancer expression database support this conclusion (https://www.oncomine.org/resource). Re-analyses of Hou and Garber lung datasets indicated that SCC express higher Kindlin-1 than adenocarcinoma and large cell lung cancer, whereas large cell lung cancer expresses low level of Kindlin-1. Re-analyses of Kindlin-1 expression in other datasets including TCGA, Su multicancer and Zhu lung databases (data not shown) of Oncomine displayed the same tendency. Collectively, Kindlin-1 expression in SCC is higher than AC at both mRNA and protein levels. In addition, the expression of Kindlin-1 is higher in well differentiated SCC than in undifferentiated LCC. These data suggest that Kindlin-1 expression is correlated with lung cancer differentiation, and Kindlin-1 could be used as a differentiation marker for SCC. Therefore, it is possible to control the differentiation of lung squamous epithelia and the SCC through regulation of Kindlin-1 expression. For the translational relevance of Kindlin-1 expression and, well differentiated SCC has been known to have low metastatic rate and low relapse after surgery and usually sensitive to radiotherapy and chemotherapy, and predicts good prognosis [23]. However, the non-squamous, non-adenomatous undifferentiated LCC displayed early metastasis, insensitive to radiotherapy and chemotherapy and predicts poor prognosis for the patients [22].

Interestingly, the expression pattern of Kindlin-2 in lung cancer is different from that of Kindlin-1. Instead of expression in tumor cells, Kindlin-2 is mainly expressed in the stroma of various types of lung cancer. Kindlin-2 expression was found in fibroblasts and smooth muscle cells of the blood vessels. We demonstrated that in this report Kindlin-1 and Kindlin-2 are differentially expressed in various types of lung cancer. Like Kindlin-1, Kindlin-2 is also higher expressed in NSCLC than in SCLC, indicating that Kindlin-2 tends to express in epithelia-originated but not in...
neuroendocrine-originated lung cancers. However, Kindlin-2 expression profile was just opposite with that of Kindlin-1 in NSCLC. Kindlin-2 expression levels obey an order of LCC>AC>SCC, suggesting that Kindlin-2 plays an opposite role in NSCLC: higher Kindlin-2 expression corresponds to a worse lung cancer phenotype. Due to the inadequate cases of LCC in our study we could not clearly establish the relationship between Kindlin-2 expression level and the outcome of LCC patients. However, the positive correlation for Kindlin-2 expression with poor disease outcome was supported by data from Oncomine.

Figure 4. Kindlin-1 and Kindlin-2 oppositely regulate lung cancer cell migration and invasion. a. Expression of Kindlin-1 and Kindlin-2 in the secondary de novo SCC from an invasive SCC patient. A. Kindlin-1 expression in the de novo SCC. B. Kindlin-2 expression in the de novo SCC from the same patient as in A. b. Left panel: Differential expression of Kindlin-1, Kindlin-2, E-cadherin and Vimentin in various lung cancer cell lines controlled by actin for loading. Right panel: Quantification of the relative protein expression levels. c. Left panel: Stable expression of Kindlin-1 in H1299 cells. Indicated are mixed stable clones that express Flag-Kindlin-1. Right panel: Quantification of the relative protein levels for Kindlin-1 regulated N-cadherin and Vimentin. d. Kindlin-1 and Kindlin-2 differentially regulate migration in H1299 cells. Displayed is the quantification and plot as mean ± SEM from three independent experiments. Statistical analyses between different cell groups were examined by Student’s t test. ** represents for p<0.01. e. Kindlin-1 and Kindlin-2 differentially regulate the mRNA levels of MMPs analyzed by qPCR in H1299 cells stably expressing Kindlin-1 and Kindlin-2. Insert shows expression of Kindlin-1 and Kindlin-2 in the stable mixed clones applied in qPCR. f. Left panels: Expression of Kindlin-1 downregulates N-cadherin and Knockdown of Kindlin-2 downregulates N-cadherin. Right panels: Quantification of the relative protein levels for Kindlin-1- and Kindlin-2-regulated N-cadherin. Statistical analyses between different cell groups were examined by Student’s t test. ** represents for p<0.01. g. Expression of Kindlin-2 in lymph node metastasized large cell lung cancer patient. A. Primary large cell lung cancer; B. Lymph node metastasized large cell lung cancer from the same patient.

doi:10.1371/journal.pone.0050313.g004

Figure 5. Kindlin-1 and Kindlin-2 oppositely regulate tumor growth in implanted xenograft. a. Tumor growth curve. The tumor volume of H1299-Flag-Kindlin-1 group is significantly smaller than the Flag-BAP group (p<0.01 as analyzed by Student’s t test) at day 22 and meanwhile the volume of Flag-Kindlin-2 group is obviously larger than the Flag-BAP group (p<0.01 as analyzed by Student’s t test). b. Tumors recovered from mice at day 27. c. Left panel: Determination of expressions of N-cadherin and Vimentin from tumor xenografts stably expressing Kindlin-1, Kindlin-2 and the control BAP by Western blot analyses. Right panel: Quantification of the relative protein levels for Kindlin-1- and Kindlin-2-regulated N-cadherin and Vimentin. Statistical analyses between different tumor groups were examined by Student’s t test. ** represents for p<0.01.

doi:10.1371/journal.pone.0050313.g005
database. By re-analyzing the Hou and Garber lung datasets we found that Kindlin-1 expression in SCC is high while Kindlin-2 expression is low in the same cohort of SCC patients. It is generic that Kindlin-2 expression is lower in SCC than that of AC. Taken together, these findings strongly indicated that Kindlin-1 and Kindlin-2 play an opposite role in the regulation of NSCLC behaviors. The differential expression and counteracting role of Kindlin-1 and Kindlin-2 in lung cancers were depicted in a working model as shown in Figure 6. Furthermore, it seems that the sum of Kindlin-1 and Kindlin-2 remains constant in an NSCLC patient, thus the biological role of the molecular switch between Kindlin-1 and Kindlin-2 leaves an open question for future investigations.

Intriguingly, Kindlin-1 has recently been reported to promote breast cancer lung metastasis [13], a role that is just opposite for what we found in lung cancer. This is the first report that a counteracting role of Kindlin-1 in human cancers. To this end, we found that Kindlin-1 exhibits an inhibitory role for tumor growth and invasion in lung cancer. Therefore, it was of particular interest to answer why Kindlin-1 functions adversely in breast cancer as that of it in lung cancer. As a possible mechanism accounting for the diverse roles of Kindlin-1 in cancers, we identified that Kindlin-1 downregulates Wnt signaling component Axin2 and upregulates tight junction molecules such as Claudin-1 and -3 in lung cancer cells (Zhan et al., data not shown). Adversely, Kindlin-1 upregulates Wnt signaling component β-catenin and EMT markers Vimentin and fibronectin in breast cancer cells [13]. In a small cohort of lung cancer patients, Sin et al also found that Kindlin-1 is overexpressed in lung primary tumors and Kindlin-1 expression is strongly associated with metastasis-free survival of patients with lung adenocarcinomas [13]. The findings of Sin et al indicated that Kindlin-1 is overexpressed in primary tumors but not in metastatic tumors in lung cancer, which is in agreement with our conclusion that Kindlin-1 is overexpressed in well differentiated SCC but low or not expressed in large cell or small cell lung cancers.

Besides the counteracting role of Kindlin-1 in breast cancer and lung cancer cells, surprisingly we uncovered the opposite role of Kindlin-1 and Kindlin-2 in the regulation of lung cancer progression. Kindlin-1 inhibited whereas Kindlin-2 promoted lung cancer cell migration and invasion in an in vitro assay. The in vivo tumor implant experiment clearly demonstrated that Kindlin-1 inhibited but Kindlin-2 accelerated xenograft tumor growth. Mechanistically, Kindlin-1 downregulated epithelial to mesenchymal transition markers N-cadherin and Vimentin, whereas Kindlin-2 expression upregulated these markers as indicated in Fig. 4f. These findings suggest that Kindlin-1 and Kindlin-2 play an opposite role in the regulation of EMT process, which account for the mechanistic interpretation for Kindlin-1 and Kindlin-2 involvement in the regulation of lung cancer cell invasion. Furthermore, in clinical samples we found that Kindlin-1 expression is lower at the tumor invasive front as shown in Fig. 4a, suggesting that Kindlin-1 inhibited lung cancer cell migration, invasion as well as tumor growth at these cellular motile structures. In comparison, Kindlin-2 is highly expressed at these structures and apparently promoted lung cancer cell migration and invasion as previous reports [10,12]. All together, at layers of cells, xenograft tumor implants and patient tumor tissue samples Kindlin-1 and Kindlin-2 displayed their opposite biological functions in lung cancer.

In summary, in this study we found that Kindlin-1 and Kindlin-2 play distinct roles in lung cancer progression. Kindlin-1 predominantly expressed in well differentiated NSCLC and inhibited the malignant progression including tumor invasion and growth, whereas Kindlin-2 mainly expressed in poorly differentiated NSCLC and promoted tumor invasion and growth. Kindlin-1 can be potentially used as a marker for evaluation of lung cancer differentiation while Kindlin-2 may be a hopeful therapeutic target for LCC.

Acknowledgments

We thank Yan tang and Feng Li from Peking University for technical assistants, and Dr. Staffan Stromblad from Karolinska Institutet for comments on writing.

Author Contributions

Conceived and designed the experiments: JZ HZ. Performed the experiments: JZ MN JH JD JC BM. Analyzed the data: JZ XZ YG.
References

1. Travis WD, Travis LB, Devesa SS (1995) Lung cancer. Cancer 75: 191–202.

2. Travis WD (2002) Pathology of lung cancer. Clin Chest Med 23: 65–81, viii.

3. Larjava H, Ploow EF, Wu C (2008) Kindlins: essential regulators of integrin signalling and cell-matrix adhesion. EMBO Rep 9: 1203–1208.

4. Kloeker S, Major MB, Calderwood DA, Ginsburg SH, Jones DA, et al. (2004) The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. J Biol Chem 279: 6824–6833.

5. Montanez E, Ussar S, Schillerer M, Bosl M, Zent R, et al. (2008) Kindlin-2 controls bidirectional signaling of integrins. Genes Dev 22: 1325–1330.

6. Kindler T (1954) Congenital poikiloderma with traumatic bulla formation and progressive cutaneous atrophy. Br J Dermatol 66: 104–111.

7. Jobard F, Boudjadar B, Caux F, Hadji-Rabia S, Has C, et al. (2003) Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome. Hum Mol Genet 12: 925–933.

8. Siegel DH, Ashton GH, Penages HG, Lee JV, Feiler HS, et al. (2003) Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet 73: 174–187.

9. Weinstein EJ, Bournier M, Heude R, Zakeri H, Bauer C, et al. (2003) URPI: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas. Biochim Biophys Acta 1637: 207–216.

10. An Z, Dobra K, Lock JG, Stromblad S, Hjerpe A, et al. (2010) Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration. Int J Cancer 127: 1999–2008.

11. Gong X, An Z, Wang Y, Guan L, Fang W, et al. (2010) Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death. Cancer Lett 299: 54–62.

12. Shen Z, Ye Y, Dong L, Vainionpaa S, Mustonen H, et al. (2012) Kindlin-2: a novel adhesion protein related to tumor invasion, lymph node metastasis, and patient outcome in gastric cancer. Am J Surg 203: 222–229.

13. Sin S, Bonin F, Petit V, Meseure D, Lallemand F, et al. (2011) Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J Natl Cancer Inst 103: 1323–1337.

14. Taha S, Somji S, Toni C, Garrett SH, Zhou XD, et al. (2011) Kindlin-2 expression in arsenite- and cadmium-transformed bladder cancer cell lines and in archival specimens of human bladder cancer. Urology 77: 1501–1507.

15. Kruger M, Moser M, Ussar S, Thievessen I, Laber CA, et al. (2008) SILAC mouse for quantitative proteomics uncovers kindlin-1 as an essential factor for red blood cell function. Cell 134: 353–364.

16. Moer M, Nieswandt B, Ussar S, Pougajova M, Fassler R (2008) Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 14: 325–330.

17. Wu WB, Zhang Q, Li Y, Shian SL, Li XY, et al. (2012) [Expression of kindlins and angiopoietins in acute myeloid leukaemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20: 7–11.

18. Harris ES, Smith TL, Springett GM, Weyrich AS, Zimmerman GA (2012) Leukocyte adhesion deficiency-I variant syndrome (LAD-Iv, LAD-III): molecular characterization of the defect in an index family. Am J Hematol 87: 311–313.

19. van de Vijver E, Madshalea A, Noald O, Holand SM, Uzel G, et al. (2012) Hematologically important mutations: leukocyte adhesion deficiency (first update). Blood Cells Mol Dis 48: 53–61.

20. Malinin NL, Plow EF, Bytova TV (2010) Kindlins in FERM adhesion. Blood 115: 4011–4017.

21. Dowling JJ, Gibbs E, Russell M, Goldman D, Minarcik J, et al. (2008) Kindlin-2 is an essential component of intercalated discs and is required for vertebral cardiac structure and function. Circ Res 102: 425–431.

22. Shin MS, Jackson LK, Shelton RW Jr, Greene RE (1996) Giant cell carcinoma of the lung. Clinical and roentgenographic manifestations. Chest 89: 366–369.

23. Yaroczyan AA, Neubert JC, Lee JS, et al. (2000) Cancer Medicine. B C Decker. 1227–1292. ISBN 1-55009-115-1.